MCID: PTT006
MIFTS: 57

Pituitary Adenoma

Categories: Genetic diseases, Rare diseases, Endocrine diseases, Gastrointestinal diseases, Cancer diseases

Aliases & Classifications for Pituitary Adenoma

MalaCards integrated aliases for Pituitary Adenoma:

Name: Pituitary Adenoma 12 28 51 14 69
Pituitary Neoplasms 41 69
Adenoma of the Pituitary Gland 12
Pituitary Adenomas 36

Classifications:



External Ids:

Disease Ontology 12 DOID:3829
MeSH 41 D010911
NCIt 46 C3329
KEGG 36 H01102

Summaries for Pituitary Adenoma

MalaCards based summary : Pituitary Adenoma, also known as pituitary neoplasms, is related to pituitary adenoma 4, acth-secreting and non-functioning pituitary adenoma. An important gene associated with Pituitary Adenoma is AIP (Aryl Hydrocarbon Receptor Interacting Protein), and among its related pathways/superpathways are Transcriptional misregulation in cancer and ErbB signaling pathway. The drugs Hydrocortisone and Prednisone have been mentioned in the context of this disorder. Affiliated tissues include pituitary, thyroid and brain, and related phenotypes are growth/size/body region and endocrine/exocrine gland

Wikipedia : 72 Pituitary adenomas are tumors that occur in the pituitary gland. Pituitary adenomas are generally... more...

Related Diseases for Pituitary Adenoma

Diseases in the Pituitary Adenoma family:

Pituitary Adenoma 1, Multiple Types Pituitary Adenoma 5, Multiple Types
Pituitary Adenoma 3, Multiple Types

Diseases related to Pituitary Adenoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 297)
# Related Disease Score Top Affiliating Genes
1 pituitary adenoma 4, acth-secreting 34.4 GNAS USP8
2 non-functioning pituitary adenoma 33.8 GH1 SST
3 silent pituitary adenoma 33.8 AIP MEN1
4 pituitary adenoma 1, multiple types 33.7 AIP GH1 IGF1 PRL SST
5 acth-secreting pituitary adenoma 33.6 CRH GNAS POMC PRL
6 null pituitary adenoma 33.6 AIP MEN1
7 growth hormone secreting pituitary adenoma 33.3 AIP GNAS PRL SST SSTR2
8 chiasmal syndrome 32.4 POMC PRL SST
9 functioning pituitary adenoma 32.0 AIP GH1 MEN1 POMC PRL SST
10 tsh producing pituitary tumor 31.7 GH1 PRL SST TSHB
11 conn's syndrome 31.6 CRH GNAS MEN1 POMC
12 chromophobe adenoma 31.2 GH1 GHRH POMC PRL TRH
13 adrenal gland hyperfunction 30.9 CRH GH1 GHRH POMC PRL SST
14 pituitary apoplexy 30.9 AIP POMC PRL
15 lymphocytic hypophysitis 30.6 GH1 POMC
16 pituitary adenoma, prolactin-secreting 30.6 AIP GH1 GNAS IGF1 MEN1 POMC
17 multiple endocrine neoplasia, type i 30.1 GNAS MEN1 PRL SST
18 mccune-albright syndrome 30.1 GH1 GNAS IGF1 PRL SST
19 gigantism 29.9 AIP GH1 GHRH GPR101 PRL
20 carney complex variant 29.9 AIP GNAS GPR101 MEN1 POMC
21 craniopharyngioma 29.8 IGF1 POU1F1 PRL TRH
22 neuroendocrine tumor 29.8 MEN1 SST SSTR2
23 growth hormone deficiency 29.7 GH1 GHRH IGF1
24 hypoadrenalism 29.6 CRH GH1 POMC
25 adenohypophysitis 29.6 GH1 POMC PRL TRH
26 empty sella syndrome 29.6 GH1 POMC PRL TRH
27 pheochromocytoma 29.5 CRH MEN1 POMC SST
28 adenoma 29.5 AIP GH1 GNAS GPR101 IGF1 MEN1
29 pituitary carcinoma 29.5 CRH GNAS POMC SST SSTR2
30 hyperpituitarism 29.5 AIP GH1 GHRH IGF1 POMC PRL
31 tuberculum sellae meningioma 29.5 GHRH POMC PRL
32 suprasellar meningioma 29.4 POMC TRH TSHB
33 hyperthyroidism 29.4 GH1 GNAS PRL SST TRH
34 fibrous dysplasia 29.3 GH1 GNAS IGF1 PRL SST
35 insulin-like growth factor i 28.9 GH1 GHRH IGF1 PRL SST
36 pituitary hormone deficiency, combined, 2 28.9 GH1 IGF1 POMC POU1F1 PRL TSHB
37 hypopituitarism 28.8 CRH GH1 GHRH IGF1 POMC POU1F1
38 pituitary tumors 28.6 AIP GH1 GNAS IGF1 MEN1 POMC
39 acromegaly 28.4 AIP GH1 GHRH GNAS GPR101 IGF1
40 hyperprolactinemia 28.3 GH1 GHRH IGF1 POMC PRL SST
41 body mass index quantitative trait locus 11 28.1 CRH GH1 GHRH GNAS IGF1 POMC
42 familial isolated pituitary adenoma 12.5
43 pituitary adenoma 5, multiple types 12.4
44 pituitary adenoma 2, growth hormone-secreting 12.4
45 pituitary adenoma 3, multiple types 12.4
46 aip-related familial isolated pituitary adenomas 12.1
47 functionless pituitary adenoma 12.0
48 acroleukopathy, symmetric 11.5
49 pituicytoma 11.3
50 somatomammotropinoma 11.1

Graphical network of the top 20 diseases related to Pituitary Adenoma:



Diseases related to Pituitary Adenoma

Symptoms & Phenotypes for Pituitary Adenoma

MGI Mouse Phenotypes related to Pituitary Adenoma:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.13 GNAS SST IGF1 SSTR5 MEN1 AIP
2 endocrine/exocrine gland MP:0005379 10.11 GNAS IGF1 SSTR5 MEN1 TRH AIP
3 homeostasis/metabolism MP:0005376 10.1 GNAS SST SSTR2 IGF1 SSTR5 MEN1
4 liver/biliary system MP:0005370 9.76 PRL GNAS MEN1 AIP POMC CRH
5 neoplasm MP:0002006 9.43 PRL GNAS IGF1 MEN1 AIP POMC
6 nervous system MP:0003631 9.36 PRL GNAS SST SSTR2 IGF1 MEN1

Drugs & Therapeutics for Pituitary Adenoma

Drugs for Pituitary Adenoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 156)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Hydrocortisone Approved, Vet_approved Phase 4,Phase 3,Phase 2 50-23-7 657311 5754
2
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
3
Menthol Approved Phase 4 2216-51-5 16666
4
Octreotide Approved, Investigational Phase 4,Phase 3,Phase 2 83150-76-9 6400441 383414
5
Cabergoline Approved Phase 4,Phase 3,Phase 2 81409-90-7 54746
6
Dopamine Approved Phase 4,Phase 3,Phase 2 51-61-6, 62-31-7 681
7
Somatostatin Approved, Investigational Phase 4,Phase 2,Phase 3 38916-34-6, 51110-01-1 53481605
8 lanreotide Approved Phase 4 108736-35-2
9
Cefazolin Approved Phase 4 25953-19-9 33255 656510
10
Cefdinir Approved Phase 4 91832-40-5 6915944
11
Cefuroxime Approved Phase 4 55268-75-2 5479529 5361202
12
Clindamycin Approved, Vet_approved Phase 4 18323-44-9 29029
13
Sulfamethoxazole Approved Phase 4 723-46-6 5329
14
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
15
Liraglutide Approved Phase 4 204656-20-2 44147092
16
Metformin Approved Phase 4 657-24-9 4091 14219
17
Zinc Approved, Investigational Phase 4 7440-66-6 32051 23994
18
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 1 59-30-3 6037
19
leucovorin Approved, Nutraceutical Phase 4,Phase 1 58-05-9 143 6006
20
Butyric Acid Experimental, Investigational Phase 4 107-92-6 264
21
Lactitol Investigational Phase 4 585-86-4 3871
22 Anesthetics Phase 4,Phase 1
23 Anti-Inflammatory Agents Phase 4,Phase 2
24 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2
25 Cortisol succinate Phase 4,Phase 3,Phase 2
26 glucocorticoids Phase 4,Phase 2
27 Hormone Antagonists Phase 4,Phase 2,Phase 3,Early Phase 1
28 Hormones Phase 4,Phase 2,Phase 3,Early Phase 1
29 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3,Early Phase 1
30 Hydrocortisone 17-butyrate 21-propionate Phase 4,Phase 3,Phase 2
31 Hydrocortisone acetate Phase 4,Phase 3,Phase 2
32 Hydrocortisone-17-butyrate Phase 4
33 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1
34 insulin Phase 4,Phase 2
35 Insulin, Globin Zinc Phase 4,Phase 2
36 Antiparkinson Agents Phase 4,Phase 3,Phase 2
37 Dopamine Agents Phase 4,Phase 3,Phase 2
38 Dopamine agonists Phase 4,Phase 3,Phase 2
39 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1
40 Anti-Bacterial Agents Phase 4
41 Antibiotics, Antitubercular Phase 4
42 Pharmaceutical Solutions Phase 4,Phase 3
43 HIV Protease Inhibitors Phase 4
44
protease inhibitors Phase 4
45 Angiopeptin Phase 4
46 Anti-Infective Agents Phase 4,Phase 2
47 Antimalarials Phase 4
48 Antiparasitic Agents Phase 4
49 Antiprotozoal Agents Phase 4
50 Antitubercular Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 97)

# Name Status NCT ID Phase Drugs
1 Effect of Perioperative Glucocorticoid Replacement on Prognosis of Surgical Patients With Sellar Lesions Unknown status NCT02190994 Phase 4 Hydrocortisone;Prednisone
2 Characterization of Receptors in Non-functioning Pituitary Macroadenomas Unknown status NCT00852501 Phase 4
3 Surgical Debulking of Pituitary Adenomas Completed NCT01371643 Phase 4 Octreotide LAR
4 Preoperative Octreotide Treatment of Acromegaly Completed NCT00521300 Phase 4 Octreotide
5 Octreotide Efficacy and Safety in First-line Acromegalic Patients Completed NCT00171886 Phase 4 Octreotide
6 Adipokine Profile in Patients With Cushing's Disease on Pasireotide Treatment Completed NCT03080181 Phase 4 Pasireotide 0.6 MG/ML
7 Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly Completed NCT00376064 Phase 4 Octreotide acetate and cabergoline/Octrotide and Somavert
8 Prophylactic Oral Antibiotics on Sinonasal Outcomes Following Endoscopic Transsphenoidal Surgery for Pituitary Lesions Recruiting NCT03014687 Phase 4 Placebo;Oral Antibiotics cefdinir or trimethoprim/sulfamethoxazole
9 Assessment of Changes in Metabolic Activity in Liver & Skeletal Muscle in Patients Suffering From Acromegaly Recruiting NCT02115906 Phase 4
10 Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly Recruiting NCT02060383 Phase 4 Pasireotide s.c.;Sitagliptin;Liraglutide;Insulin;Pasireotide LAR;Metformin
11 Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study. Recruiting NCT01794793 Phase 4 Pasireotide
12 A Pilot Study of Pre- and Post-operative Use of Somatuline Depot. Terminated NCT01861717 Phase 4 lanreotide
13 Cabergoline in Nonfunctioning Pituitary Adenomas Completed NCT03271918 Phase 3 Cabergoline
14 Response to Cabergoline and Pasireotide in Non-functioning Pituitary Adenomas and Resistant Prolactinomas Completed NCT01620138 Phase 2, Phase 3 Pasireotide;cabergoline
15 Study of Cabergoline in Treatment of Corticotroph Pituitary Tumor Completed NCT00889525 Phase 3 Cabergoline
16 An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease. Completed NCT01582061 Phase 3 Pasireotide sub-cutaneous
17 Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease Completed NCT01374906 Phase 3 SOM230 LAR 30 mg;SOM230 LAR 10 mg
18 Safety and Efficacy of Different Dose Levels of Pasireotide in Patients With de Novo, Persistent or Recurrent Cushing's Disease Completed NCT00434148 Phase 3 Pasireotide
19 Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome Completed NCT01371565 Phase 3 Mifepristone
20 Dopamine Agonist Treatment of Non-functioning Pituitary Adenomas Recruiting NCT02288962 Phase 3 cabergoline
21 Ga-68-DOTATOC -PET in the Management of Pituitary Tumours Recruiting NCT02419664 Phase 3
22 Efficacy and Safety Evaluation of Osilodrostat in Cushing's Disease Recruiting NCT02697734 Phase 3 osilodrostat;osilodrostat Placebo
23 Safety and Efficacy of LCI699 for the Treatment of Patients With Cushing's Disease Active, not recruiting NCT02180217 Phase 3 LCI699
24 Multicenter Evaluation of the Effect of Upfront Radiosurgery on Residual Growth Hormone-secreting Pituitary Adenoma Not yet recruiting NCT03439709 Phase 3 Lanreotide 60Mg Solution for Injection
25 Mifepristone in Children With Refractory Cushing's Disease Withdrawn NCT01925092 Phase 3 mifepristone
26 Preoperative Bexarotene Treatment for Cushing's Disease Unknown status NCT00845351 Phase 1, Phase 2 Bexarotene
27 Targeted Therapy With Gefitinib in Patients With USP8-mutated Cushing's Disease Unknown status NCT02484755 Phase 2 Gefitinib
28 Extension Study to Assess the Safety and Efficacy of Pasireotide in Patients With Cushing's Disease Completed NCT00171951 Phase 2 Pasireotide
29 An Extension Study to Assess the Long-term Safety and Efficacy of Pasireotide in Patients With Acromegaly Completed NCT00171730 Phase 2 Pasireotide
30 Sandostatin LAR Depot vs. Surgery for Treating Acromegaly Completed NCT00001860 Phase 2 Sandostatin LAR Depot versus transsphenoidal surgery
31 A Study to Assess SOM230 in Patients With Pituitary Cushing's Disease Completed NCT00088608 Phase 2 SOM230 s.c.
32 Evaluate the Efficacy and Safety of Pasireotide LAR on the Treatment of Patients With Clinically Non-Functioning Pituitary Adenoma. Recruiting NCT01283542 Phase 2 Pasireotide LAR
33 Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy Recruiting NCT00939523 Phase 2 Lapatinib
34 Enhancement of Neurocognitive Functions by Hippocampal Sparing Radiotherapy Recruiting NCT01849484 Phase 2
35 Radioactive Iodine Implants for Pan-invasive Pituitary Macroadenomas Recruiting NCT01444209 Phase 2
36 Pasireotide LAR Therapy of Silent Corticotroph Pituitary Tumors Recruiting NCT02749227 Phase 2 Pasireotide LAR
37 Treatment of Cushing's Disease With R-roscovitine Recruiting NCT02160730 Phase 2 R-roscovitine
38 Targeting Iatrogenic Cushing's Syndrome With 11β-hydroxysteroid Dehydrogenase Type 1 Inhibition Recruiting NCT03111810 Phase 2 AZD4017 and prednisolone;Placebo Oral Tablet and prednisolone
39 Study of the Efficacy and Safety of Pasireotide s.c. +/- Cabergoline in Patients With Cushing's Disease Active, not recruiting NCT01915303 Phase 2 Pasireotide with or without cabergoline
40 Safety and Efficacy of LCI699 in Cushing's Disease Patients. Active, not recruiting NCT01331239 Phase 2 LCI699
41 Rosiglitazone in Treating Patients With Pituitary Tumors Terminated NCT00616642 Phase 2 rosiglitazone maleate
42 Rosiglitazone in Treating Patients With Newly Diagnosed ACTH-Secreting Pituitary Tumor (Cushing Disease) Terminated NCT00612066 Phase 2 rosiglitazone maleate
43 Pasireotide Therapy in Patients With Nelson's Syndrome Terminated NCT01617733 Phase 2 Pasireotide
44 Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin Terminated NCT00958841 Phase 2 pasireotide LAR
45 Exploratory Study of Farletuzumab to Treat Resectable, Non-functioning Pituitary Adenomas Withdrawn NCT01203618 Phase 2 Farletuzumab
46 A Phase 1, Single Dose, Open-Label Study to Investigate the Safety and Efficacy of OTL38 Injection (OTL38) for Intra-operative Imaging of Folate Receptor-alpha Positive Pituitary Adenoma Recruiting NCT02769533 Phase 1 OTL0038;Benadryl
47 Detection of Functioning Pituitary Microadenoma: PET/MRI Versus PET/CT Recruiting NCT03404414 Phase 1 18F-FDG
48 Intraoperative Imaging of Pituitary Adenomas by OTL Active, not recruiting NCT02629549 Phase 1 OTL38
49 The Predictive Factors of Vision Recovery in Patients With Pituitary Tumor Unknown status NCT01377701
50 Prevalence of Pituitary Incidentaloma in Relatives of Patients With Pituitary Adenoma Unknown status NCT00598949

Search NIH Clinical Center for Pituitary Adenoma

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cochrane evidence based reviews: pituitary neoplasms

Genetic Tests for Pituitary Adenoma

Genetic tests related to Pituitary Adenoma:

# Genetic test Affiliating Genes
1 Pituitary Adenoma 28

Anatomical Context for Pituitary Adenoma

MalaCards organs/tissues related to Pituitary Adenoma:

38
Pituitary, Thyroid, Brain, Endothelial, Liver, Testes, Bone

Publications for Pituitary Adenoma

Articles related to Pituitary Adenoma:

(show top 50) (show all 1659)
# Title Authors Year
1
Universal Sellar Anatomical Reconstruction Using the Sellar Floor Flap after Endoscopic Pituitary Adenoma Surgery. ( 29436283 )
2018
2
Malignant transformation in non-functioning pituitary adenomas (pituitary carcinoma). ( 29299820 )
2018
3
Triptolide inhibits pituitary adenoma cell viability, migration and invasion via ADAM12/EGFR signaling pathway. ( 29288766 )
2018
4
Caveolin-1 promotes pituitary adenoma cells migration and invasion by regulating the interaction between EGR1 and KLF5. ( 29309750 )
2018
5
MicroRNA-378 regulates cell proliferation and migration by repressing RNF31 in pituitary adenoma. ( 29399147 )
2018
6
Consensus-driven in-hospital cortisol assessment after ACTH-secreting pituitary adenoma resection. ( 29143885 )
2018
7
Mortality in patients with non-functioning pituitary adenoma. ( 29344906 )
2018
8
CantA_ syndrome with coexisting familial pituitary adenoma. ( 29327300 )
2018
9
Association of retinal nerve fibre layer thickness with quantitative magnetic resonance imaging data of the optic chiasm in pituitary adenoma patients. ( 29398198 )
2018
10
Debulking surgery of pituitary adenoma as a strategy to facilitate definitive stereotactic radiosurgery. ( 29450811 )
2018
11
A thyrotropin-secreting pituitary adenoma treated with radiosurgery: Long-term outcomes. ( 29426625 )
2018
12
Risk category system to identify pituitary adenoma patients with<i>AIP</i>mutations. ( 29440248 )
2018
13
Clinical outcomes of endoscopic versus microscopic trans-sphenoidal surgery for large pituitary adenoma. ( 29417847 )
2018
14
Pediatric Pituitary Adenoma: Case Series, Review of the Literature, and a Skull Base Treatment Paradigm. ( 29404245 )
2018
15
Neurosurgical image: giant pituitary adenoma and multiple aneurysms. ( 29373931 )
2018
16
Primary meningeal melanocytoma in sellar region, simulating a nonfunctioning pituitary adenoma; a case report and literature review. ( 29382618 )
2018
17
Cerebrospinal fluid rhinorrhoea following transsphenoidal surgery for pituitary adenoma: experience in a Chinese centre. ( 28872159 )
2017
18
Intrasellar cavernous hemangioma presenting as pituitary adenoma: A report of two cases and review of the literature. ( 29189199 )
2017
19
Novel Biomarkers for Non-functioning Invasive Pituitary Adenomas were Identified by Using Analysis of microRNAs Expression Profile. ( 28315020 )
2017
20
ESR1 and its antagonist fulvestrant in pituitary adenomas. ( 28043824 )
2017
21
Reconstruction of a skull base defect after endoscopic endonasal resection of a pituitary adenoma: Sphenoid mucosal flaps. ( 29279249 )
2017
22
Large and giant pituitary adenoma resection by microscopic trans-sphenoidal surgery: Surgical outcomes and complications in 123 consecutive patients. ( 28778803 )
2017
23
Relationship between RSUME and HIF-1I+/VEGF-A with invasion of pituitary adenoma. ( 27989771 )
2017
24
'Coexisting pituitary adenoma and suprasellar meningioma-a coincidence or causation effect: report of two cases and review of the literature'. ( 28560021 )
2017
25
Central hypogonadism due to a giant, "silent" FSH-secreting, atypical pituitary adenoma: effects of adenoma dissection and short-term Leydig cell stimulation by luteinizing hormone (LH) and human chorionic gonadotropin (hCG). ( 28067604 )
2017
26
Hypopituitarism after gamma knife radiosurgery for pituitary adenoma. ( 28537768 )
2017
27
Nasal Lobular Capillary Hemangioma as a Complication after an Endoscopic Transsphenoidal Gonadotrophin-Producing Pituitary Adenoma Resection. ( 28326242 )
2017
28
A Novel Invasive-Related Biomarker in Three Subtypes of Nonfunctioning Pituitary Adenomas. ( 28093347 )
2017
29
Simultaneous Occurrence of a Pituitary Adenoma and a Foramen Magnum Meningioma: Case Report. ( 27989978 )
2017
30
An FSH and TSH pituitary adenoma, presenting with precocious puberty and central hyperthyroidism. ( 28721217 )
2017
31
Does MMP-9 Gene Polymorphism Play a Role in Pituitary Adenoma Development? ( 28194042 )
2017
32
Complex effects of apoplexy secondary to pituitary adenoma. ( 27802176 )
2017
33
Survivin overexpression is potentially associated with pituitary adenoma invasiveness. ( 29285279 )
2017
34
Intratumoral granulomatous reaction in recurrent pituitary adenoma: A unique presentation. ( 28862230 )
2017
35
Transdifferentiation of Neuroendocrine Cells: Gangliocytoma Associated With Two Pituitary Adenomas of Different Lineage in MEN1. ( 28079577 )
2017
36
Increased I^a89catenin and c-myc expression predict aggressive growth of non-functioning pituitary adenomas: An assessment using a tissue microarray-based approach. ( 28260015 )
2017
37
Multihormonal pituitary adenoma concomitant with Pit-1 and Tpit lineage cells causing acromegaly associated with subclinical Cushing's disease: a case report. ( 28865461 )
2017
38
Signal transducer and activator of transcription 3 (STAT3) promoter methylation and expression in pituitary adenoma. ( 28709401 )
2017
39
Ovarian hyperstimulation syndrome due to follicle-stimulating hormone-secreting pituitary adenomas. ( 28676954 )
2017
40
Collision tumors composed of meningioma and growth hormone-secreting pituitary adenoma in the sellar region: Case reports and a literature review. ( 29390316 )
2017
41
Effect of miR-106b on Invasiveness of Pituitary Adenoma via PTEN-PI3K/AKT. ( 28288092 )
2017
42
Folate receptor overexpression can be visualized in real time during pituitary adenoma endoscopic transsphenoidal surgery with near-infrared imaging. ( 28841122 )
2017
43
Pituitary Adenoma and Hyperprolactinemia Accompanied by Idiopathic Granulomatous Mastitis. ( 28321344 )
2017
44
Perioperative management of haemophilia A using recombinant factor VIII Fc fusion protein in a patient undergoing endoscopic nasal pituitary adenomectomy for a growth hormone-producing pituitary adenoma. ( 28906056 )
2017
45
Thyrotropin-producing pituitary adenoma simultaneously existing with Graves' disease: a case report. ( 28061802 )
2017
46
Radiological Predictors for Extent of Resection in Pituitary Adenoma Surgery. A Single-center study. ( 28899832 )
2017
47
Function of cell-cycle regulators in predicting silent pituitary adenoma progression following surgical resection. ( 29344143 )
2017
48
A Case of Pituitary Carcinoma Initially Diagnosed as an Ectopic Growth Hormone Producing Pituitary Adenoma with a High Ki-67 Labeling Index. ( 28586933 )
2017
49
T cell lymphoblastic lymphoma/leukemia within an adrenocorticotropic hormone and thyroid stimulating hormone positive pituitary adenoma: A cytohistological correlation emphasizing importance of intra-operative squash smear. ( 28295636 )
2017
50
Decreased TAp63 and I9Np63 mRNA Levels in Most Human Pituitary Adenomas Are Correlated with Notch3/Jagged1 Relative Expression. ( 28078618 )
2017

Variations for Pituitary Adenoma

Copy number variations for Pituitary Adenoma from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 55796 11 55700000 65900000 Copy number Pituitary adenoma
2 58390 11 67250504 67258578 Amplification AIP Pituitary adenoma
3 64485 12 12870301 12875305 Amplification CDKN1B Pituitary adenoma

Expression for Pituitary Adenoma

Search GEO for disease gene expression data for Pituitary Adenoma.

Pathways for Pituitary Adenoma

Pathways related to Pituitary Adenoma according to KEGG:

36
# Name Kegg Source Accession
1 Transcriptional misregulation in cancer hsa05202
2 ErbB signaling pathway hsa04012
3 Cell cycle hsa04110
4 Apoptosis hsa04210
5 Insulin signaling pathway hsa04910

GO Terms for Pituitary Adenoma

Cellular components related to Pituitary Adenoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.32 CRH GH1 GHRH GNAS IGF1 POMC
2 endosome lumen GO:0031904 8.96 GH1 PRL

Biological processes related to Pituitary Adenoma according to GeneCards Suite gene sharing:

(show all 21)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 9.88 MEN1 POU1F1 SST SSTR2 SSTR3 SSTR5
2 chemical synaptic transmission GO:0007268 9.84 CRH SST SSTR3 SSTR5
3 neuropeptide signaling pathway GO:0007218 9.76 POMC SSTR2 SSTR3
4 regulation of receptor activity GO:0010469 9.76 GH1 GHRH IGF1 POMC PRL SST
5 female pregnancy GO:0007565 9.72 CRH GNAS PRL
6 G-protein coupled receptor signaling pathway GO:0007186 9.7 CRH GHRH GNAS GPR101 POMC SST
7 positive regulation of cAMP biosynthetic process GO:0030819 9.69 CRH GHRH GNAS
8 G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.67 SSTR2 SSTR3 SSTR5
9 positive regulation of multicellular organism growth GO:0040018 9.63 GH1 GHRH POU1F1
10 cellular response to glucocorticoid stimulus GO:0071385 9.61 SSTR2 SSTR3 SSTR5
11 positive regulation of JAK-STAT cascade GO:0046427 9.6 GH1 PRL
12 adenylate cyclase-activating adrenergic receptor signaling pathway GO:0071880 9.59 GNAS GPR101
13 response to corticosterone GO:0051412 9.58 CRH TRH
14 JAK-STAT cascade involved in growth hormone signaling pathway GO:0060397 9.57 GH1 PRL
15 positive regulation of cAMP-mediated signaling GO:0043950 9.56 CRH GNAS
16 positive regulation of insulin-like growth factor receptor signaling pathway GO:0043568 9.54 GH1 GHRH IGF1
17 adenohypophysis development GO:0021984 9.52 GHRH POU1F1
18 hormone-mediated apoptotic signaling pathway GO:0008628 9.5 CRH SST SSTR3
19 somatostatin signaling pathway GO:0038170 9.43 SSTR2 SSTR3 SSTR5
20 cell-cell signaling GO:0007267 9.23 GHRH GPR101 POMC SST SSTR2 SSTR3
21 signal transduction GO:0007165 10.13 CRH GNAS GPR101 IGF1 POMC SSTR2

Molecular functions related to Pituitary Adenoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 insulin-like growth factor receptor binding GO:0005159 9.37 GNAS IGF1
2 neuropeptide binding GO:0042923 9.33 SSTR2 SSTR3 SSTR5
3 corticotropin-releasing hormone receptor 1 binding GO:0051430 9.32 CRH GNAS
4 prolactin receptor binding GO:0005148 9.26 GH1 PRL
5 hormone activity GO:0005179 9.23 CRH GH1 IGF1 POMC PRL SST
6 somatostatin receptor activity GO:0004994 9.13 SSTR2 SSTR3 SSTR5

Sources for Pituitary Adenoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....